S
Susanne Michen
Researcher at Dresden University of Technology
Publications - 13
Citations - 497
Susanne Michen is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Immunotherapy & Lymphokine-activated killer cell. The author has an hindex of 6, co-authored 10 publications receiving 327 citations.
Papers
More filters
Journal ArticleDOI
Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma
Nadja Müller,Susanne Michen,Stefanie Tietze,Katrin Töpfer,Alexander Schulte,Katrin Lamszus,Marc Schmitz,Gabriele Schackert,Ira Pastan,Achim Temme +9 more
TL;DR: It is concluded that chemokine receptor–engineered NK cells with concomitant expression of a tumor-specific CAR are a promising tool to improve adoptive tumor immunotherapy.
Journal ArticleDOI
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Katrin Töpfer,Marc Cartellieri,Susanne Michen,Ralf Wiedemuth,Nadja Müller,Dirk Lindemann,Michael Bachmann,Monika Füssel,Gabriele Schackert,Achim Temme +9 more
TL;DR: It is concluded that NK cells engineered with DAP12-based CARs are a promising tool for adoptive tumor immunotherapy.
Journal ArticleDOI
A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA.
Stefanie Tietze,Isabell Schau,Susanne Michen,Franka Ennen,Andreas Janke,Gabriele Schackert,Gabriele Schackert,Achim Aigner,Dietmar Appelhans,Achim Temme,Achim Temme +10 more
TL;DR: The results suggest that receptor-mediated uptake of otherwise noninternalized mal-PPI-based polyplexes is a promising avenue to improve siRNA therapy of cancer, and introduce a novel strategy for modular bioconjugation of protein ligands to nanoparticles.
Journal ArticleDOI
Chromosomal instability induced by increased BIRC5 /Survivin levels affects tumorigenicity of glioma cells
Marina Conde,Susanne Michen,Ralf Wiedemuth,Barbara Klink,Evelin Schröck,Evelin Schröck,Gabriele Schackert,Gabriele Schackert,Achim Temme,Achim Temme +9 more
TL;DR: Overexpression of Survivin levels promote adaptive evolution of tumors through combining induction of genetic heterogeneity with inhibition of apoptosis and indicates a DNA-repair by non-homologous end joining recombination.
Journal ArticleDOI
Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis.
Isabell Schau,Susanne Michen,Alexander Hagstotz,Andreas Janke,Gabriele Schackert,Gabriele Schackert,Dietmar Appelhans,Achim Temme,Achim Temme +8 more
TL;DR: Results suggest promising activation of innate immune response and apoptosis upon selective delivery of TLR3 agonists in tumor cells, and further studies using syngeneic and orthotopic tumor models are needed to fully exploit the potential of RICIA immunoconjugates.